Webinar: PRIA's 360° Approach to Market Access for Novel Technologies

November 12, 2026

Webinar: PRIA's 360° Approach to Market Access for Novel Technologies

An integrated strategy from concept to commercialization


Bringing a novel medical technology to market requires more than a strong product and a well-defined regulatory pathway. Success depends on aligning regulatory, quality, reimbursement, market access, patient access, and commercialization strategies early and throughout the product lifecycle.


On December 2nd, from 12-1 PM Eastern, join PRIA Healthcare for a dynamic, one-hour panel discussion featuring experts from across our core service areas as they explore how a coordinated, multidisciplinary approach can help MedTech innovators anticipate challenges, overcome barriers to adoption, and accelerate commercialization.


What You'll Learn


Our panelists will share real-world insights and practical strategies across key areas of commercialization, including:

  • Regulatory & Quality: How early regulatory decisions and quality considerations can shape development timelines, reimbursement opportunities, and market readiness.
  • Reimbursement Strategy: How to navigate coding, coverage, and payment complexities and build a sustainable reimbursement pathway.
  • Market Access & Payer Engagement: How to anticipate payer expectations, strengthen your value proposition, and develop strategies that support coverage and adoption.
  • Patient Access Programs: How to address prior authorization, appeals, and other barriers that can delay patient access to innovative technologies.
  • Go-to-Market Strategy: How to align clinical, economic, and commercial priorities to prepare your organization and field teams for a successful launch.

Click the Icon below to share this with your network

By PRIA Healthcare • September 10, 2026
The latest issue of PRIA Pages covers all of our many activities throughout the first and second quarters of 2026, combined into one comprehensive summary!
The first in a series on the shifting landscape of patient access
By Chelsy Peet • August 20, 2026
The first in a series on the shifting landscape of patient access, from inside the team that fights for the patient's first stamp on their passport.
RAPID and the Long Effort to Close Medicare's Coverage Gap by Tonya Dowd and Sam Murray
By Tonya Dowd & Sam Murray • August 17, 2026
FDA authorization does not guarantee timely Medicare coverage. RAPID is CMS’s latest attempt to narrow that gap—and potentially one of its most consequential.
PRIA's webinar, How Payers Decide: Coverage, Evidence, and Value in MedTech Commercialization
July 28, 2026
PRIAs webinar, How Payers Decide: Coverage, Evidence, and Value in MedTech Commercialization featuring Dr. Julie Kessel and Dr. Dot Verbrugge
Stop Guessing What FDA Wants by Sam Murray
By Sam Murray • June 4, 2026
Stop Guessing What FDA Wants
Regulatory Meets Reimbursement: What MedTech Innovators Need to Know About FDA Breakthrough & Beyond
June 3, 2026
Regulatory Meets Reimbursement: What MedTech Innovators Need to Know About FDA Breakthrough and Beyond
You Got Your 510(k). Now What?
By Suzy Engwall • May 28, 2026
You Got Your 510(k). Now What?
Right Sizing Your Quality System by Sam Murray
By Sam Murray, Head of Regulatory & Quality • May 21, 2026
Right Sizing Your Quality System
Cleared for takeoff: Insights from a Medtech First Officer
By Suzy Engwall • May 19, 2026
Five Mistakes MedTech StartUps Make Before Their First VAC Meeting
Using Regulatory as a Strategy and Not a Milestone
By Sam Murray, PRIA • May 14, 2026
Using Regulatory as a Strategy and Not a Milestone
Reading the Water: Navigating What Matters in Regulatory and Quality  - Sam Murray, PRIA
By Sam Murray, Head of Regulatory & Quality • May 6, 2026
An informative article series from PRIA Healthcare's Head of Regulatory and Quality, Sam Murray
Medical device strategy CMS/FDA RAPID program
By Tonya Dowd & Sam Murray • April 24, 2026
Examining the impact of the RAPID program, accelerating Medicare access for Breakthrough Devices by aligning FDA approval & CMS coverage, earlier.